THE DUBERSTEIN GROUP INC. for PHRMA INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Patent reform - HR 9, Innovation Act; S 1137, PATENT Act; HR 2045, Targeting Rogue and Opaque Letters Act of 2015; S 632, STRONG Patents Act of 2015; HR 1896, Demand Letter Transparency Act of 2015.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
| DAVID J SCHIAPPA | — |
Health Issues HCR
21st Century Cures - HR 6, 21st Century Cures Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KENNETH DUBERSTEIN | — |
| DANIEL P MEYER | — |
Medicare/Medicaid MMM
Sustainable growth rate - HR 2, Medicare Access and CHIP Reauthorization Act of 2015. Medicare Advantage - HR 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
Budget/Appropriations BUD
Budget issues and possible healthcare related pay-fors.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
Trade (domestic/foreign) TRD
Trade issues, including Trade Promotion Authority - HR 1890, Bipartisan Congressional Trade Priorities and Accountability Act of 2015; S 995, Bipartisan Congressional Trade Priorities and Accountability Act of 2015; HR 1314, Trade Act of 2015; HR 2146, Defending Public Safety Employees' Retirement Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
| DAVID J SCHIAPPA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.